Boston, MA 10/21/2013 (wallstreetpr) – Investors of Keryx Biopharmaceuticals (NASDAQ:KERX) have nothing to complain about during the last week. The shares of company have rallied from low of $8.7 to highs of $11.90 giving a return of more than 36% in less than 5 days.
But it does seem that current rally may not sustain for long and the stock may actually be heading for a reversal. This lightning move by stock has been because of some rating upgrades by analysts of Brean Capital and Roth Capital. Analysts at Roth seem quite smitten by company’s prospects and have given it a price target of 24 dollars. This translates into an almost 200% potential upmove from levels when the report initially was made public. Another encouraging target has been provided by Roth Capital which has upgraded its price target to $20. Both these upgrades are based on company’s drug Zerenex’s market potential and what it can do for the company in near future. This actually places company on a strong footing in chronic diseases market and has the potential to catapult the company in altogether different orbit.
But if market sources are to be believed then it seems that markets are running ahead of the fundamentals. Skeptics are of the view that the basis of these rating upgrades has a very low probability of realization. Optimists might view this as a once in a life time opportunity to get hold of a multi bagger at low levels. But it seems that there are larger operators who are unloading their positions to make a cool profit of more than 36% in less than a week. Company is scheduled to come up with is earning numbers in second week of November. In last quarter, company posted an EPS of 10 cents which was 30% lower than market estimates. And as per current consensus, company should be able to manage a full year EPS of 42 cents. But it remains to be seen whether stock prices would move any higher after the current rally or not.
